New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
16:12 EDTXOMAXOMA says Phase 3 PATH trial meets primary endpoint
XOMA announced the 837-patient Phase 3 PATH trial of perindopril arginine combined with amlodipine besylate is statistically significantly superior to either compound alone in reducing both sitting diastolic and sitting systolic blood pressure after six weeks of treatment. This FDC, containing a patent-protected proprietary form of perindopril, was licensed by XOMA as part of a U.S. commercial and development rights agreement signed with Servier for their perindopril franchise. Servier markets the fixed-dose combination product, COVERAM, in 91 countries outside the U.S. The FDC appeared to be well tolerated in the trial, and there were no unexpected serious adverse events reported. The most common adverse events included mild to moderate edema, cough and headache, which are known side effects of the individual components of the FDC, the company said.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:16 EDTXOMAAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 16, 2014
07:23 EDTXOMAIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 10, 2014
13:01 EDTXOMAXOMA management to meet with Maxim
Subscribe for More Information
October 9, 2014
09:08 EDTXOMAXOMA initiates dosing in XOMA 358 Phase 1 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use